证券代码：002317 编号：2026-002 广东众生药业股份有限公司投资者关系活动记录表 | | √ □特定对象调研 □分析师会议 | | --- | --- | | | □媒体采访 □业绩说明会 | | 投资者关系活动 类别 | □新闻发布会 □路演活动 | | | □现场参观 □一对一沟通 | | | □其他（ ） | | 参与单位及人员 | 中信证券股份有限公司、广发证券股份有限公司、宝盈基金管 | | | 理有限公司、上海理成资产管理有限公司分析师、研究员 | | 时间 | 2026 年 1 月 23 日 10:30～11:30 | | 地点 | 众生睿创会议室 | | 形式 | 现场交流 | | 上市公司 | 1、公司副总裁 陈小新 | | 接待人员 | 2、公司董事会秘书 杨威 1、众生睿创与齐鲁制药关于RAY1225注射液的合作情况。 | | | 答：众生睿创与齐鲁制药于 2026 年 1 月 16 日签署《许可 协议》，众生睿创授权齐鲁制药在中国地区（包括中国大陆、 | | | 香港、澳门、台湾，统称"许可地区"）内对 RAY1225 注射液 | | | （以下简称"许可产品"）进行生产与 ...

Core Viewpoint - Guangdong Zhongsheng Pharmaceutical Co., Ltd. announced that its subsidiary, Guangdong Yishu Pharmaceutical Co., Ltd., has completed the industrial and commercial change registration, obtaining a new business license [1] Group 1 - The announcement confirms the authenticity, accuracy, and completeness of the disclosed information by the company and its board members [1] - The change was approved by the Zhaoqing Market Supervision Administration [1] - The completion of the registration process is a significant step for the subsidiary, indicating operational progress [1]

（编辑 楚丽君） 证券日报网讯 1月21日，众生药业发布公告称，近日，广东众生药业股份有限公司收到控股子公司广东 逸舒制药股份有限公司完成工商变更登记的通知。经肇庆市市场监督管理局核准，逸舒制药已办理完成 工商变更登记手续，并取得新的《营业执照》。 ...

Market Overview - The Chinese traditional medicine sector experienced a decline of 0.39% on January 21, with Zhongsheng Pharmaceutical leading the drop [1] - The Shanghai Composite Index closed at 4116.94, up 0.08%, while the Shenzhen Component Index closed at 14255.12, up 0.7% [1] Stock Performance - Notable gainers in the traditional medicine sector included: - *ST Changyao: Closed at 0.64, up 20.75% with a trading volume of 519,700 shares and a turnover of 32.17 million yuan [1] - Tianmu Pharmaceutical: Closed at 22.29, up 8.47% with a trading volume of 128,100 shares and a turnover of 282 million yuan [1] - Wanbangde: Closed at 17.82, up 5.13% with a trading volume of 196,800 shares and a turnover of 34.2 million yuan [1] - Conversely, Zhongsheng Pharmaceutical saw a decline of 4.26%, closing at 21.12 with a trading volume of 685,100 shares and a turnover of 144.9 million yuan [2] Capital Flow - The traditional medicine sector experienced a net outflow of 281 million yuan from major funds, while retail investors saw a net inflow of 78.63 million yuan [2] - Major funds showed significant net inflows in stocks such as Yunnan Baiyao, which had a net inflow of 78.68 million yuan, and Wanbangde with a net inflow of 22.17 million yuan [3]

具体变更情况如下： | 变更项目 | 变更前 | 变更后 | | --- | --- | --- | | 法定代表人 | 刘政文 | 胡清华 | 证券代码：002317 公告编号：2026-004 广东众生药业股份有限公司 关于子公司完成工商变更登记的公告 本公司及董事会全体成员保证信息披露内容的真实、准确和完整，没有虚假 记载、误导性陈述或重大遗漏。 近日，广东众生药业股份有限公司收到控股子公司广东逸舒制药股份有限公 司（以下简称"逸舒制药"）完成工商变更登记的通知。经肇庆市市场监督管理 局核准，逸舒制药已办理完成工商变更登记手续，并取得新的《营业执照》。 特此公告。 广东众生药业股份有限公司董事会 二〇二六年一月二十一日 第 1页 共 1页 ...

Group 1 - The core point of the news is that Zhongsheng Pharmaceutical's stock price has dropped by 5.26%, currently trading at 20.90 CNY per share, with a total market capitalization of 17.764 billion CNY [1] - Zhongsheng Pharmaceutical, established on December 31, 2001, and listed on December 11, 2009, is primarily engaged in the research, production, and sales of pharmaceuticals [1] - The company's revenue composition includes 53.03% from traditional Chinese medicine sales, 38.12% from chemical drug sales, 6.13% from Chinese medicinal materials and decoction pieces, 2.14% from raw materials and intermediates, and 0.58% from other sources [1] Group 2 - From the perspective of fund holdings, one fund under Taixin Fund has a significant position in Zhongsheng Pharmaceutical, with Taixin Smart Quantitative Stock Mixed Fund A (013033) holding 15,000 shares, accounting for 1.94% of the fund's net value [2] - The estimated floating loss for the fund today is approximately 17,400 CNY [2] - Taixin Smart Quantitative Stock Mixed Fund A (013033) was established on May 22, 2025, with a current scale of 12.5156 million CNY and a year-to-date return of 8.16%, ranking 1626 out of 8844 in its category [2]

Group 1 - The company announced a licensing agreement for the RAY1225 injection project, allowing Qilu Pharmaceutical to produce and commercialize the drug in China, while the company retains all rights outside of China [1] - The total payment for the licensing agreement is 1 billion yuan, which includes an upfront payment of 200 million yuan and milestone payments up to 800 million yuan, along with a double-digit percentage of net sales after the product launch [1] - RAY1225 is an innovative peptide drug with global intellectual property rights, showing promising results in clinical trials for weight loss, with a weight reduction of 10.1%-15.1% after 24 weeks of treatment [2] Group 2 - The company is seeing initial success in its transformation with core products like the Compound Thrombus Tong series and Brain Thrombus Tong capsules selected for national and regional procurement, indicating a strategy of "volume for price" to maintain profitability [3] - The company has a pipeline of innovative drugs, including ZSP1601 for MASH and RAY1225 for weight loss, with several Phase III clinical trials completed [3] - The company expects revenue growth from 2.53 billion yuan in 2025 to 3 billion yuan in 2027, with net profit projections of 310 million yuan in 2025 and 570 million yuan in 2026, reflecting a significant turnaround [4]

Overview - Guangdong Zhongsheng Pharmaceutical Co., Ltd. has approved the use of idle raised funds for cash management and idle self-owned funds for entrusted wealth management, ensuring that these actions do not affect the normal operation of fundraising investment plans [2][3] Cash Management - The company has authorized the use of up to RMB 180 million of idle raised funds for cash management, with a management period of twelve months from the date of the board's approval [2] - The funds can be rolled over within the approved limit, with the actual investment amount not exceeding RMB 180 million at any given time [2] Entrusted Wealth Management - The company and its subsidiaries have been authorized to use up to RMB 400 million of idle self-owned funds for entrusted wealth management, also with a twelve-month period from the board's approval [3] - Similar to cash management, the funds can be rolled over within the approved limit, with the actual transaction amount not exceeding RMB 400 million at any given time [3] Investment Products - On January 19, 2026, the company and its subsidiaries signed agreements with Dongguan Bank to purchase structured deposit products using idle funds, with specific amounts allocated to each entity [4] - The structured deposits are principal-protected with floating returns, denominated in RMB [4] - Additionally, on the same date, Zhongsheng Ruichuang signed an agreement with CITIC Bank to purchase a structured deposit product using RMB 20 million of idle self-owned funds [8] Risk Control Measures - The company will adhere to prudent investment principles and strictly follow the board-approved investment limits [12] - It will enhance market analysis and adjust investment strategies as needed, implementing risk control measures promptly [12] - The company has established detailed management systems to prevent investment risks and will conduct regular audits of the entrusted wealth management situation [13] Impact on Company - The use of idle funds for cash management and entrusted wealth management is expected to improve the efficiency of fund utilization and enhance the overall performance of the company, benefiting all shareholders [15]

Market Overview - The three major A-share indices collectively closed lower on January 20, with a total market turnover of approximately 2.8 trillion yuan, and over 2,200 stocks rose, including 63 stocks hitting the daily limit [1] Institutional Ratings - A total of 11 buy ratings were issued by institutions today, covering 9 stocks, with Hunan YN and Keda receiving 2 buy ratings each [2] - Among the stocks with buy ratings, 6 companies provided earnings forecasts for 2025, with Hunan YN expected to see a net profit increase of 114.81% year-on-year, followed by Zhenyu Technology and Keda with expected increases of 106.74% and 59.82% respectively [2] Industry Focus - The power equipment industry was the most favored by institutions, with 4 stocks including Hunan YN and Keda listed [2] - The automotive and food & beverage industries also attracted institutional attention, each having 2 stocks featured [2] Institutional Trading - In the top trading list, 17 stocks had net buying amounts exceeding 10 million yuan, with Hunan Baiyin leading at 80.83 million yuan, followed by Tongyu Communications at 55.55 million yuan [4] - Among the net selling stocks, Sanwei Communication faced the highest net sell of 194 million yuan [4] Northbound Capital - 12 stocks on the northbound trading list saw net buying, with Tongyu Communications leading at 97.57 million yuan, followed by Tiantong Co. and Hunan Baiyin, both exceeding 60 million yuan [6] Company Announcements - ST Saiwei (300044) announced an expected net profit loss of 720 million to 1.02 billion yuan for 2025, influenced by litigation and arbitration judgments [7] - Kangxin New Materials (600076) plans to acquire 51% of Wuxi Yubang Semiconductor Technology for 392 million yuan, marking its expansion into the semiconductor sector [8] - Huadian Technology (601226) signed a procurement contract worth approximately 374 million yuan for a wind-solar hydrogen project [8] - China Merchants Energy (601872) plans to build 4 container ships with a total investment of up to 1.324 billion yuan [9] - Anhui Construction (600502) received project bids totaling 13.76 million yuan for two projects [9]

证券日报网讯 1月20日，众生药业发布公告称，公司使用4000万元闲置募集资金购买东莞银行96天期保 本浮动收益结构性存款，预期年化收益率1.30%至1.70%，起息日2026年1月21日，到期日2026年4月27 日；截至2026年1月20日，前十二个月内公司及子公司累计已到期理财产品本金及收益均已如期收回。 （文章来源：证券日报） ...